The expression of KAI1/CD82 and MRP-1/CD9 in transitional cell carcinoma of bladder （TCCB） and its clinical significance were investigated. Immunohistochemistry was used to detect KAI1/CD82 and MRP-1/CD9 protein exp...The expression of KAI1/CD82 and MRP-1/CD9 in transitional cell carcinoma of bladder （TCCB） and its clinical significance were investigated. Immunohistochemistry was used to detect KAI1/CD82 and MRP-1/CD9 protein expression in 52 TCCB specimens. Correlation between the expression of KAI1/CD82 and MRP-1/CD9 to clinicopathologic factors was statistically analyzed. The results showed that the positive rate of KAI1/CD82 and MRP-1/CD9 in TCCB was 50% and 61.5%, respectively. The MRP-1/CD9 and KAI1/CD82 expression was significantly associated with grade of TCCB （P〈0.05）, but no correlation was found between MRP-1/CD9 or KAI1/CD82 expression and clinical stage of TCCB （P〉0.05）. The expression level of MRP-1/CD9 and KAI1/CD82 in recurrent TCCB samples was lower than that in non-recurrent samples （P〈0.05）. Meanwhile, the correlation between the KAI1/CD82 expression and MRP-1/CD9 expression was statistically significant （r=0.316, P〈0.05）. It was concluded that KAI1/CD82 and MRP-1/CD9 expression may be important prognostic indicators and potentially useful for assessing the biological behavior of TCCB.展开更多
Objective： The aim of this study was to investigate the MRP-1/CD9mRNA expression in lung cancer and normal lung tissues and the relationship between its expression and pathologic grades, clinical stages, metastasis a...Objective： The aim of this study was to investigate the MRP-1/CD9mRNA expression in lung cancer and normal lung tissues and the relationship between its expression and pathologic grades, clinical stages, metastasis and prognosis. Methods： To observe MRP-1/C9mRNA expression, tissue microarray （TMA） containing 54 lung cancers and 10 normal lung tissues was prepared and Fluorescence in situ hybridization was used. Results： The positive rate of MRP-1/CD9 expression was 48.1% in lung cancer, lower than that of normal lung tissues. The statistical difference was significant （P〈0.05）. Its protein expression had no relationship with the patients＇ ages, sex and the macroscopic type of tumor, but had relationships with the histological type, clinical stage, differentiated degree and metastasis. The expression in non-small cell lung cancer （NSCLC） was higher than that in small cell lung cancer （SCLC）; in well-moderately differentiated group was higher than that in poorly differentiated group; Earlier period group （I＋II） was higher than in later period group （Ⅲ＋Ⅳ）; and in group without lymphoid metastasis was higher than in patients with lymphoid metastasis. Conclusion： The progression of the lung cancer maybe related with the descended MRP-1/Cd9 expression, which may be useful in evaluating the prognosis of cancer patients.展开更多
目的研究鸦胆子油乳对人卵巢癌细胞系SKOV3细胞及SKOV3裸鼠移植瘤的生长抑制作用。方法 MTT法测定不同浓度鸦胆子油乳单独及联合顺铂对人卵巢癌细胞SKOV3的生长抑制作用。采用人卵巢癌细胞SKOV3移植方法构建卵巢癌裸鼠模型,将32只卵巢...目的研究鸦胆子油乳对人卵巢癌细胞系SKOV3细胞及SKOV3裸鼠移植瘤的生长抑制作用。方法 MTT法测定不同浓度鸦胆子油乳单独及联合顺铂对人卵巢癌细胞SKOV3的生长抑制作用。采用人卵巢癌细胞SKOV3移植方法构建卵巢癌裸鼠模型,将32只卵巢癌裸鼠随机分为4组,每组8只。空白对照组(简称对照组)、鸦胆子油乳组(简称鸦胆子组)、鸦油顺铂联合组(简称联合组)及顺铂组。A、B组分别每隔2日腹腔注射生理盐水、鸦胆子油乳注射液0.2 m L/20 g,联合组第1天腹腔注射顺铂0.2 m L(3 mg/kg),第2天腹腔注射0.2 m L/20 g鸦胆子油乳注射液,D组每隔2日腹腔注射顺铂0.2 m L(3 mg/kg)。各组均注射6次,末次腹腔注射后48 h断颈处死裸鼠,观察腹腔肿瘤组织病灶形成情况,取肿瘤病灶标本进行HE染色和Western blot检测肿瘤组织运动相关蛋白MRP-1/CD9和整合素α-5表达水平。结果鸦胆子油乳对人卵巢癌SKOV3细胞的抑制作用呈剂量—时间依赖关系,鸦胆子油乳与顺铂联合应用对人卵巢癌SKOV3细胞的抑制作用显著高于这两种药物的单独应用。Western blot结果显示鸦胆子组和顺铂组MRP-1/CD9和整合素α-5的表达均上调,且差异有统计学意义(P<0.05),但联合组表达下调,差异有统计学意义(P<0.05)。结论鸦胆子油乳注射液腹腔给药治疗卵巢癌具有可行性和一定的疗效性,并且鸦胆子油乳可能以MRP-1/CD9和整合素α-5为靶点抑制肿瘤细胞侵袭和转移,但具体的抗肿瘤机制尚未明确。展开更多
基金The project was supported by a grant from National Natural Sciences Foundation of China (No. 30571858).
文摘The expression of KAI1/CD82 and MRP-1/CD9 in transitional cell carcinoma of bladder （TCCB） and its clinical significance were investigated. Immunohistochemistry was used to detect KAI1/CD82 and MRP-1/CD9 protein expression in 52 TCCB specimens. Correlation between the expression of KAI1/CD82 and MRP-1/CD9 to clinicopathologic factors was statistically analyzed. The results showed that the positive rate of KAI1/CD82 and MRP-1/CD9 in TCCB was 50% and 61.5%, respectively. The MRP-1/CD9 and KAI1/CD82 expression was significantly associated with grade of TCCB （P〈0.05）, but no correlation was found between MRP-1/CD9 or KAI1/CD82 expression and clinical stage of TCCB （P〉0.05）. The expression level of MRP-1/CD9 and KAI1/CD82 in recurrent TCCB samples was lower than that in non-recurrent samples （P〈0.05）. Meanwhile, the correlation between the KAI1/CD82 expression and MRP-1/CD9 expression was statistically significant （r=0.316, P〈0.05）. It was concluded that KAI1/CD82 and MRP-1/CD9 expression may be important prognostic indicators and potentially useful for assessing the biological behavior of TCCB.
基金This work was supported by a grant from Tianjin Science and Technology Committee (No. 033804211)
文摘Objective： The aim of this study was to investigate the MRP-1/CD9mRNA expression in lung cancer and normal lung tissues and the relationship between its expression and pathologic grades, clinical stages, metastasis and prognosis. Methods： To observe MRP-1/C9mRNA expression, tissue microarray （TMA） containing 54 lung cancers and 10 normal lung tissues was prepared and Fluorescence in situ hybridization was used. Results： The positive rate of MRP-1/CD9 expression was 48.1% in lung cancer, lower than that of normal lung tissues. The statistical difference was significant （P〈0.05）. Its protein expression had no relationship with the patients＇ ages, sex and the macroscopic type of tumor, but had relationships with the histological type, clinical stage, differentiated degree and metastasis. The expression in non-small cell lung cancer （NSCLC） was higher than that in small cell lung cancer （SCLC）; in well-moderately differentiated group was higher than that in poorly differentiated group; Earlier period group （I＋II） was higher than in later period group （Ⅲ＋Ⅳ）; and in group without lymphoid metastasis was higher than in patients with lymphoid metastasis. Conclusion： The progression of the lung cancer maybe related with the descended MRP-1/Cd9 expression, which may be useful in evaluating the prognosis of cancer patients.
文摘目的研究鸦胆子油乳对人卵巢癌细胞系SKOV3细胞及SKOV3裸鼠移植瘤的生长抑制作用。方法 MTT法测定不同浓度鸦胆子油乳单独及联合顺铂对人卵巢癌细胞SKOV3的生长抑制作用。采用人卵巢癌细胞SKOV3移植方法构建卵巢癌裸鼠模型,将32只卵巢癌裸鼠随机分为4组,每组8只。空白对照组(简称对照组)、鸦胆子油乳组(简称鸦胆子组)、鸦油顺铂联合组(简称联合组)及顺铂组。A、B组分别每隔2日腹腔注射生理盐水、鸦胆子油乳注射液0.2 m L/20 g,联合组第1天腹腔注射顺铂0.2 m L(3 mg/kg),第2天腹腔注射0.2 m L/20 g鸦胆子油乳注射液,D组每隔2日腹腔注射顺铂0.2 m L(3 mg/kg)。各组均注射6次,末次腹腔注射后48 h断颈处死裸鼠,观察腹腔肿瘤组织病灶形成情况,取肿瘤病灶标本进行HE染色和Western blot检测肿瘤组织运动相关蛋白MRP-1/CD9和整合素α-5表达水平。结果鸦胆子油乳对人卵巢癌SKOV3细胞的抑制作用呈剂量—时间依赖关系,鸦胆子油乳与顺铂联合应用对人卵巢癌SKOV3细胞的抑制作用显著高于这两种药物的单独应用。Western blot结果显示鸦胆子组和顺铂组MRP-1/CD9和整合素α-5的表达均上调,且差异有统计学意义(P<0.05),但联合组表达下调,差异有统计学意义(P<0.05)。结论鸦胆子油乳注射液腹腔给药治疗卵巢癌具有可行性和一定的疗效性,并且鸦胆子油乳可能以MRP-1/CD9和整合素α-5为靶点抑制肿瘤细胞侵袭和转移,但具体的抗肿瘤机制尚未明确。
